Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced a change in the date of its upcoming earnings conference call, now set for April 3, 2023, where it will report its financial results for Q4 and the full year of 2022. The company will file its Annual Report on Form 10-K on March 31, 2023. The conference call will take place at 5:30 a.m. PT / 8:30 a.m. ET, allowing stakeholders to discuss financial results and highlights. Oncocyte specializes in precision diagnostics, offering tests like DetermaIO™, VitaGraft™, and the upcoming DetermaCNI™, which aim to provide critical insights for physicians and patients.

Positive

• Announcement of upcoming earnings call on April 3, 2023, may indicate transparency and investor engagement.
• Management will discuss financial results and company highlights, suggesting a proactive communication strategy.

Negative

• The press release does not provide any recent financial performance metrics, leaving investors without critical data.

IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results on Monday, April 3, 2023. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. The company plans to file its Annual Report on Form 10-K on Friday, March 31, 2023.

Interested parties may access the live call via telephone by dialing (877) 407-9716 for domestic callers or (201) 493-6779 for international callers. The live webinar of the call may be accessed by visiting the “Events & Presentation” section of the Company’s website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

About Oncocyte
Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy.

DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation

Investor Contact
Caroline Corner
ICR Westwicke
(415) 202-5678
caroline.corner@westwicke.com 

Source: Oncocyte Corporation

FAQ

What date is Oncocyte's earnings conference call for Q4 2022?

Oncocyte's earnings conference call for Q4 2022 is scheduled for April 3, 2023.

When will Oncocyte file its Annual Report on Form 10-K?

Oncocyte plans to file its Annual Report on Form 10-K on March 31, 2023.

What is the purpose of Oncocyte's earnings call?

The earnings call will discuss Oncocyte's financial results for Q4 and the full year of 2022, along with company highlights.

How can I access Oncocyte's earnings call?

You can access Oncocyte's earnings call by phone at (877) 407-9716 (domestic) or (201) 493-6779 (international), or via their website.